Werewolf Therapeutics, Inc. HOWL 深 滬
等待開盤 07-21 09:30:00 美东时间
1.41
+0.010
+0.71%
華盛通- 最 高1.435
- 今 開1.43
- 成交量 40.85万股
- 最 低 1.35
- 昨 收 1.40
- 總市值 6327.18万
- 52周最高 4.18
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.595
- 委 比 -82.85%
- 總股本 4487.36万
- 歷史最高 23.99
- 量 比 0.80
- 振 幅 6.07%
- 歷史最低 0.595
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics' Chief Medical Officer, Randi Isaacs, will speak at the KidneyCAN 7th Annual Summit on July 17-18 in Boston. Her presentation will focus on the company's innovative approach to conditionally activated cytokines, specifically WTX-124, a tumor-activated IL-2 molecule designed to enhance anti-tumor activity while reducing systemic side effects. The company is currently enrolling patients in a clinical trial for advanced or meta...
07-09 12:00
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
An update from Werewolf Therapeutics ( ($HOWL) ) is now available. On June 12, ...
06-14 04:42
Werewolf Therapeutics to Participate in the BIO International Convention
Werewolf Therapeutics' Chief Medical Officer, Randi Isaacs, will participate in a panel discussion at the BIO International Convention on 'Conditionally Active Biologics' to explore their potential in reducing systemic toxicity while enhancing anti-tumor activity. The company highlights its INDUKINE molecules, with WTX-124 showing promising results, including a patient with cutaneous squamous cell carcinoma in remission for over a year. Werewolf ...
06-12 12:00
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Werewolf Therapeutics, Inc. announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, during the Jefferies Global Healthcare Conference. A live webcast will be accessible at [link] and an archived replay will be available for 90 days. The company, focused on developing conditionally activated therapeutics to stimulate...
05-29 12:00
Patient With Advanced Skin Cancer In Remission Over Year After Clinical Trial Of Werewolf Therapeutics' investigational Novel Conditionally Activated IL-2 pro-Drug WTX-124
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threateningSkin Cancer Awareness Month in May shines a spotlight on the
05-21 04:03
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6
Wedbush analyst Robert Driscoll maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $8 to $6.
05-10 00:58
Werewolf Therapeutics Q1 EPS $(0.40) Beats $(0.44) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.44) by 9.09 percent. This is a 2.56 percent decrease over losses of $(0.39) per share
05-08 19:11
Analysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
03-13 20:50
美股大行评级 | 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106863358302064640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元</p> <p>• HC Wainwright & Co.：维持LifeMD(LFMD)"买入"评级，目
03-13 09:38
